TiGenix NV

TiGenix NV (TiGenix) is a publicly held Belgium-based biomedical company. TiGenix is engaged in the development of innovative local treatments for damaged cartilage and osteoarthritis joints. It markets its flag ship product, ChondroCelect, as a regenerative medicine to treat cartilage defects. TiGenix product pipeline consists of tgx002, which is in pre-clinical development stage for cartilage regeneration in the knee; and tgx003 for the repair of meniscal lesions. TiGenix currently focuses on developing a portfolio of products that address specific musculoskeletal problems. It has established academic collaborations with Katholieke University of Leuven and the University of Hasselt to support its research platform. TiGenix is headquartered in Leuven, Belgium.

Street: 
Romeinse straat 12, bus 2
City: 
Leuven
Postcode: 
3001
Federal State : 
Belgium
WebSite: 
www.tigenix.com
Fax: 
32-16-396070

Company Index Score

Current Index Score Historical Index Score
  • TiGenix NV currently scores 50 % in the index.
  • TiGenix NV is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • TiGenix NV is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets